Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 54 of 948 for:    tablet | Japan

A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02372097
Recruitment Status : Completed
First Posted : February 26, 2015
Results First Posted : May 13, 2016
Last Update Posted : May 13, 2016
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to investigate the bioequivalence of 2 tablets of SYR-472 25 milligram (mg) and 1 tablet of SYR-472 50 mg administered to healthy adult males.

Condition or disease Intervention/treatment Phase
Healthy Drug: SYR-472 Phase 1

Detailed Description:
Bioequivalence of 2 SYR-472 25 mg tablets and 1 SYR-472 50 mg tablet administered to healthy adult males will be investigated in a randomized, open-label, crossover study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Crossover Phase 1 Study to Evaluate the Bioequivalence Following a Single Oral Dose Administration of SYR-472 25mg and 50mg Tablets in Healthy Adult Male Subjects
Study Start Date : March 2015
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Arm Intervention/treatment
Experimental: Group A
Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
Drug: SYR-472
SYR-472 25mg, 50mg

Experimental: Group B
Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
Drug: SYR-472
SYR-472 25mg, 50mg




Primary Outcome Measures :
  1. AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Unchanged SYR-472 (SYR-472Z) [ Time Frame: Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period ]
  2. Cmax: Maximum Observed Plasma Concentration for SYR-472Z [ Time Frame: Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period ]

Secondary Outcome Measures :
  1. AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for SYR-472Z [ Time Frame: Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period ]
  2. Tmax: Time to Reach the Cmax for SYR-472Z [ Time Frame: Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period ]
  3. MRT: Mean Residence Time From Time Zero to Infinity for SYR-472Z [ Time Frame: Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period ]
  4. Apparent Terminal Elimination Rate Constant (λz) for SYR-472Z [ Time Frame: Day 1: pre dose (within 3 hours prior to dosing), and at multiple time points (up to 168 hours) post dose in each period ]
  5. Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2 ]
    Collection of AEs commenced from the time that the participant was first administered study drug in Period 1 (Day 1). Routine collection of AEs continued until the end (hospital discharge) of Period 2 (Day 29).

  6. Number of Participants With TEAEs Related to Vital Signs [ Time Frame: Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2 ]
  7. Number of Participants With TEAEs Related to Body Weight [ Time Frame: Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2 ]
  8. Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values [ Time Frame: Day 1 of Period 1 up to the day of hospital discharge (Day 29) in Period 2 ]
  9. Number of Participants Who Had Abnormal and Clinically Significant 12-lead Electrocardiograms (ECG) Findings After Study Drug Administration [ Time Frame: Baseline up to 7 days after the last dose of study drug (Day 8) in each period ]
    Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Participants who understand the outline of the clinical study and are capable of complying with their responsibilities as participants, as judged by the investigator or sub investigator.
  2. Participants who can sign and date the informed consent form before the initiation of the study procedure.
  3. Healthy Japanese adult males.
  4. Participants who are 20 to 35 years of age at the time of informed consent.
  5. Participants who weigh 50.0 kilogram (kg) or more with a body mass index (BMI) of 18.5 to less than 25.0 kilogram per square meter (kg/m^2) in the screening period.

Exclusion Criteria:

  1. Participants who were administered any investigational product within 16 weeks (112 days) before the start of the study drug administration in stage 1.
  2. Participants who have received SYR-472 in the past.
  3. Employees of the study site, their family members, those who are in a dependency relationship with employees of the study site involved in the conduct of the study (for example [e.g.], spouse, parents, children, brothers and sisters), and those who might be coerced to consent to participate in the study.
  4. Participants who have poorly controlled, clinically significant abnormalities of the nervous system, cardiovascular system, lung, liver, kidneys, metabolism, gastrointestinal system, urinary system, or endocrinological system, which possibly may affect study participation or study results.
  5. Participants who have a positive urine drug test in the screening period.
  6. Participants who need to use drugs or foods listed in the table of prohibited concomitant drugs and foods.
  7. Participants who have a history of hypersensitivity or allergy to drugs (including SYR-472 and its ingredients).
  8. Participants who currently have or recently had (within the past 6 months) gastrointestinal disease that may affect drug absorption (malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [at least once a week] heartburn, surgical intervention [e.g., cholecystectomy]).
  9. Participants with a past history of cancer.
  10. Participants who are positive for any of the following during the screening period: hepatitis B virus surface antigen (HBsAg), antibody against hepatitis C virus (HCV), human immunodeficiency virus (HIV) antigen, anti-HIV antibody, or serological test for syphilis.
  11. Participants with difficulty having blood collected from a peripheral vein.
  12. Participants who donated 200 milliliter (mL) or more of whole blood within the 4 weeks (28 days) or 400 mL or more of whole blood within the 12 weeks (84 days) before starting the study drug administration in stage 1.
  13. Participants who donated a total of 800 mL or more of whole blood within the 52 weeks (364 days) before starting the study drug administration in stage 1.
  14. Participants who donated blood components within the 2 weeks (14 days) before starting the study drug administration in stage 1.
  15. Participants who show clinically significant abnormalities in electrocardiogram (ECG) during the screening period or on Day 1 (before the study drug administration).
  16. Participants who have laboratory test abnormalities suggestive of a clinically significant primary disease or who have abnormal values in any of the following parameters: alanine aminotransferase (ALT) or aspartate serum transaminase AST exceeding 1.5 times the upper limit of the normal range.
  17. Participants who are unlikely to comply with the study protocol or are ineligible for the study for any other reason, as judged by the investigator or sub investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02372097


Locations
Layout table for location information
Japan
Fukuoka, Japan
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Takeda

Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02372097     History of Changes
Other Study ID Numbers: SYR-472-1005
U1111-1167-0746 ( Other Identifier: WHO )
JapicCTI-152813 ( Registry Identifier: JapicCTI )
JapicCTI-R160849 ( Registry Identifier: JapicCTI )
First Posted: February 26, 2015    Key Record Dates
Results First Posted: May 13, 2016
Last Update Posted: May 13, 2016
Last Verified: April 2016